PF-07328948

• Description :

  PF-07328948 is an orally effective BDK (branch chain ketoacid dehydrogenase kinase) inhibitor, with IC50 of 110 nM. PF-07328948 acts as a BCKDH (branch chain ketoacid dehydrogenase) enzyme complex degrader to enhance BCAA (branch chain amino acid) catabolism. PF-07328948 improves metabolic and heart failure end points in rats[1].

• UNSPSC :

  12352101

• Target :

  Endogenous Metabolite

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/pf-07328948.html

• Purity :

  99.88

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  FC1=C(C=C(C(F)=C1OC)C2=C(C(O)=O)SC3=CC(F)=CC=C23)F

• Molecular Formula :

  C16H8F4O3S

• Molecular Weight :

  356.29

• References & Citations :

  [1]Filipski KJ, et al. Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948. J Med Chem. 2024 Nov 19.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [2936625-34-0]